Research Analysts Issue Forecasts for RARE FY2025 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at Wedbush reduced their FY2025 EPS estimates for Ultragenyx Pharmaceutical in a research report issued on Wednesday, November 5th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of ($5.84) per share for the year, down from their prior forecast of ($5.58). Wedbush currently has a “Neutral” rating and a $34.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($1.30) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.22) EPS, Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.73) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($0.55) EPS and FY2029 earnings at $0.78 EPS.

Several other research firms have also weighed in on RARE. Canaccord Genuity Group cut their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. TD Cowen cut their price target on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday. Truist Financial reduced their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday. Morgan Stanley lowered their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Finally, Wells Fargo & Company initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, October 20th. They issued an “overweight” rating and a $65.00 target price on the stock. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $82.75.

Ultragenyx Pharmaceutical Stock Down 1.0%

NASDAQ:RARE opened at $30.63 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $25.81 and a 12-month high of $53.04. The firm has a market capitalization of $2.95 billion, a P/E ratio of -5.54 and a beta of 0.30. The stock’s fifty day simple moving average is $31.47 and its 200-day simple moving average is $32.85.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). The business had revenue of $159.93 million for the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.Ultragenyx Pharmaceutical’s revenue was up 14.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.40) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS.

Insiders Place Their Bets

In related news, CFO Howard Horn sold 7,942 shares of the company’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. This represents a 7.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the sale, the executive vice president directly owned 73,271 shares in the company, valued at $2,283,857.07. This represents a 3.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 10,456 shares of company stock worth $328,486. 5.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently made changes to their positions in RARE. GAMMA Investing LLC lifted its position in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 323 shares in the last quarter. Parallel Advisors LLC increased its stake in Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 669 shares during the last quarter. Assetmark Inc. lifted its position in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,169 shares during the last quarter. Finally, Covestor Ltd grew its holdings in shares of Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 369 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.